Rx (Prescription Medicine)
USD $ 219.00
Bevaro 100mg Injection 是一种关键药物，用于治疗多种癌症。其活性成分为 Bevacizumab，属于靶向治疗药物，可抑制血管内皮生长因子（VEGF）。VEGF 是一种促进新血管生长的蛋白质，而新血管为肿瘤提供生长和转移所需的营养。通过阻断 VEGF，Bevaro 能使肿瘤缺乏血液供应，从而减缓或停止其生长并阻止转移。它通常作为联合治疗方案，用于治疗转移性结直肠癌、非小细胞肺癌、胶质母细胞瘤以及某些类型的肾癌和卵巢癌。Bevaro 100mg Injection 的剂量和用法由医疗专业人员根据具体癌症类型、分期及患者整体健康状况确定。常见副作用可能包括高血压、疲劳、腹泻以及尿中出现蛋白质。严重副作用也可能发生，因此必须与医生讨论潜在风险。Bevaro 100mg Injection 应储存在受控环境温度下，避光保存，并置于儿童不易触及的地方。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Strength | |
| Brand Name | |
| Molecule | |
| Strength | 100 Mg |
| Medicine Form | Injection |
| Pack Quantity | 1 Vial |
| Packaging Type | Vial |
| Medicine Type | Generic |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Bevacizumab 100 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
